Study details
Enrolling now
SPARKLE Trial: Crizanlizumab vs. Placebo for Frequent Vaso-Occlusive Crises in Sickle Cell Disease
Novartis Pharmaceuticals
NCT IDNCT06439082ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Target enrollment
315
Study length
about 5.5 years
Ages
12–100
Locations
13 sites in AL, DC, FL +8
About this study
Researchers are testing whether crizanlizumab, a treatment, is more effective than placebo at reducing the frequency of vaso-occlusive crises in adults and adolescents with sickle cell disease. The trial will last 2003 days and involve approximately 315 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Crizanlizumab
- 2.Take Placebo
PhasePhase 3
DrugCrizanlizumab
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low6%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
crizanlizumab
Endpoints
Secondary: Absolute change from baseline in hemoglobin, Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)